Skip Navigation

European Heart Journal 2003 24(5):381-383; doi:10.1016/S0195-668X(02)00699-1
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mann, J.F.E
Right arrow Articles by Franke, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mann, J.F.E
Right arrow Articles by Franke, J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Looking for people at high cardiovascular risk? Look at serum-creatinine

J.F.E Manna,*, I Dulau-Floreab and J Frankeb

a Department of Nephrology and Hypertension, Schwabing General Hospital, LMU, Kolner Platz 1, 80804 Munich, Germany
b German Institute for High Blood Pressure Research, Heidelberg, Germany

* Corresponding author. Tel.: +49-89-3068-2386; fax: +49-89-3068-3917
E-mail address: johannes.mann@kms.mhn.de

The first 10% of the full text of this article appears below.

See doi:10.1016/S1095-668X(02)00526-2for the article to which this editorial refers.

When patients present to hospital with an acute myocardial infarction, the major long-term aims are to preserve myocardial function and to prevent cardiovascular events. To this end and beyond, the corrected interpretation of serum-creatinine as a marker of glomerular filtration rate (GFR) as well as of future cardiovascular and renal events is helpful. In this issue, Hillege and collaborators1 provide compelling evidence for people with acute myocardial infarction (a) that even mildly reduced GFR is highly predictive for the development of heart failure and (b) that ACE inhibition with captopril preserves renal and cardiac function better than placebo over 1 year. The data apply to people without severe heart failure or hypotension . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial
H.L. Hillege, W.H. van Gilst, D.J. van Veldhuisen, G. Navis, D.E. Grobbee, P.A. de Graeff, and D. de Zeeuw
EHJ 2003 24: 412-420. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
J. J. Brugts, E. Boersma, M. Chonchol, J. W. Deckers, M. Bertrand, W. J. Remme, R. Ferrari, K. Fox, M. L. Simoons, and on behalf of the EUROPA Investigators
The Cardioprotective Effects of the Angiotensin-Converting Enzyme Inhibitor Perindopril in Patients With Stable Coronary Artery Disease Are Not Modified by Mild to Moderate Renal Insufficiency: Insights From the EUROPA Trial
J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2148 - 2155.
[Abstract] [Full Text] [PDF]